Abstract

Capturing disease progression in amyotrophic lateral sclerosis (ALS) is challenging and refinement of progression markers is urgently needed. This study introduces new motor unit number index (MUNIX), motor unit size index (MUSIX) and compound muscle action potential (CMAP) parameters called M50, MUSIX200 and CMAP50. M50 and CMAP50 indicate the time in months from symptom onset an ALS patient needs to lose 50% of MUNIX or CMAP in relation to the mean values of controls. MUSIX200 represents the time in months until doubling of the mean MUSIX of controls. We used MUNIX parameters of Musculi abductor pollicis brevis (APB), abductor digiti minimi (ADM) and tibialis anterior (TA) of 222 ALS patients. Embedded in the D50 disease progression model, disease aggressiveness and accumulation were analyzed separately. M50, CMAP50 and MUSIX200 significantly differed among disease aggressiveness subgroups (p < 0.001) regardless of disease accumulation. ALS patients with a low M50 had a significantly shorter survival compared to high M50 (median 32 versus 74 months). M50 preceded the loss of global function (median of about 14 months). M50, CMAP50 and MUSIX200 characterize the disease course in ALS in a new way and may be applied as early measures of disease progression.

Details

Title
Motor unit number index (MUNIX) loss of 50% occurs in half the time of 50% functional loss according to the D50 disease progression model of ALS
Author
Ebersbach, Theresa 1 ; Roediger, Annekathrin 1 ; Steinbach, Robert 1 ; Appelfeller, Martin 1 ; Tuemmler, Anke 1 ; Stubendorff, Beatrice 1 ; Axer, Hubertus 1 ; Witte, Otto W. 2 ; Grosskreutz, Julian 3 

 Friedrich Schiller University, Department of Neurology, Jena University Hospital, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794) 
 Friedrich Schiller University, Department of Neurology, Jena University Hospital, Jena, Germany (GRID:grid.9613.d) (ISNI:0000 0001 1939 2794); Jena University Hospital, Center for Healthy Ageing, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224) 
 University of Lübeck, Precision Neurology, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672); University of Lübeck, Cluster of Excellence Precision Medicine in Inflammation, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672) 
Pages
3981
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2785044911
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.